Skip to main content
Erschienen in: Reactions Weekly 1/2012

01.08.2012 | Case report

Cisplatin/doxorubicin/epirubicin

Hepatitis C reactivation: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death
  • life-threatening
  • hospitalisation
  • disability
  • congenital anomaly
  • requires intervention to prevent permanent impairment or damage
Literatur
1.
Zurück zum Zitat Sung PS, Bae SH, Jang JW, Song do S, Kim HY, Yoo SH, Park CH, Kwon JH, Song MJ, You CR, Choi JY, Yoon SK.Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. Korean Journal of Hepatology 17: 299-306, No. 4, Dec 2011. Available from: URL: http://dx.doi.org/10.3350/kjhep.2011.17.4.299 - South Korea Sung PS, Bae SH, Jang JW, Song do S, Kim HY, Yoo SH, Park CH, Kwon JH, Song MJ, You CR, Choi JY, Yoon SK.Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. Korean Journal of Hepatology 17: 299-306, No. 4, Dec 2011. Available from: URL: http://​dx.​doi.​org/​10.​3350/​kjhep.​2011.​17.​4.​299 - South Korea
Metadaten
Titel
Cisplatin/doxorubicin/epirubicin
Hepatitis C reactivation: 4 case reports
Publikationsdatum
01.08.2012
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2012
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201214140-00060

Weitere Artikel der Ausgabe 1/2012

Reactions Weekly 1/2012 Zur Ausgabe